Androgen replacement therapy after prostate cancer treatment

Current Urology Reports

Volumn 11, Issue 6, 2010, Pages 393-399

  Khera, Mohit ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen; Hypogonadism; Prostate cancer; Prostatectomy; Testosterone

Indexed keywords

GONADORELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE ENANTATE;

ANDROGEN THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; HUMAN; HYPOGONADISM; PENIS ERECTION; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

EID: 77958086445     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-010-0143-3     Document Type: Review

References (52)

1. A Morgentaler 2009 Testosterone therapy in men with prostate cancer: scientific and ethical considerations J Urol 181 972 979 10.1016/j.juro.2008.11. 031 19150547 This is an excellent review on the ethical considerations of testosterone replacement therapy after prostate cancer treatment.
2. A Morales AM Black LE Emerson 2009 Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations BJU Int 103 62 64 1:CAS:528:DC%2BD1MXitFyqtrY%3D 10.1111/j.1464-410X.2008.07882.x 18671790
3. A Morgentaler 2008 Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer J Sex Med 5 1834 1840 10.1111/j.1743-6109.2008.00889.x 18547385
4. American Cancer Society. How many men get prostate cancer? Available at http://www.cancer.org/Cancer/ProstateCancer/OverviewGuide/prostate-cancer- overview-key-statistics. Accessed August 2010.
5. T Mulligan MF Frick QC Zuraw, et al. 2006 Prevalence of hypogonadism in males aged at least 45 years: the HIM study Int J Clin Pract 60 762 769 1:CAS:528:DC%2BD28XovFyktLc%3D 10.1111/j.1742-1241.2006.00992.x 16846397 (Pubitemid 43881152)
6. C Steidle S Schwartz K Jacoby, et al. 2003 AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function J Clin Endocrinol Metab 88 2673 2681 1:CAS:528: DC%2BD3sXkslCrs74%3D 10.1210/jc.2002-021058 12788872
7. JD Dean C Carnegie J Rodzvilla T Smith 2004 Long-term effects of testim(r) 1% testosterone gel in hypogonadal men Rev Urol 6 Suppl 6 S22 S29 16985908
8. M Bolla L Collette L Blank, et al. 2002 Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 103 106 1:CAS:528:DC%2BD38Xlt1Ohuro%3D 10.1016/S0140-6736(02)09408-4 12126818 (Pubitemid 34786197)
9. EM Messing J Manola M Sarosdy, et al. 1999 Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1781 1788 1:STN:280:DC%2BD3c%2FlsFOltw%3D%3D 10.1056/NEJM199912093412401 10588962
10. IM Thompson PJ Goodman CM Tangen, et al. 2003 The influence of finasteride on the development of prostate cancer N Engl J Med 349 215 224 1:CAS:528:DC%2BD3sXlsVGjsbs%3D 10.1056/NEJMoa030660 12824459 (Pubitemid 36859473)
11. C Huggins CV Hodges 1941 The effect of castration, of estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate Cancer Res 1 293 297 1:CAS:528:DyaH3MXkvVCrtw%3D%3D
12. A Morgentaler 2006 Testosterone and prostate cancer: an historical perspective on a modern myth Eur Urol 50 935 939 1:CAS:528:DC%2BD28Xht1erur%2FL 10.1016/j.eururo.2006.06.034 16875775 (Pubitemid 44486489)
13. R Shabsigh ED Crawford A Nehra KM Slawin 2009 Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review Int J Impot Res 21 9 23 1:CAS:528:DC%2BD1MXktl2lug%3D%3D 10.1038/ijir.2008.31 18633357 This article is one of the largest meta-analyses assessing the incidence of prostate cancer in men treated with testosterone. They found no increased incidence of prostate cancer in men treated with testosterone.
14. OM Calof AB Singh ML Lee, et al. 2005 Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials J Gerontol A Biol Sci Med Sci 60 1451 1457 16339333
15. Endogenous Hormones and Prostate Cancer Collaborative Group AW Roddam NE Allen P Appleby TJ Key 2008 Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 170 183 1:CAS:528:DC%2BD1cXivFygsrg%3D 10.1093/jnci/djm323 18230794 (Pubitemid 351480553)
16. JR Monath DL McCullough LJ Hart JP Jarow 1995 Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen Urology 46 58 61 1:STN:280:DyaK2MzivVWrtQ%3D%3D 10.1016/S0090-4295(99) 80159-9 7541587
17. S Bhasin TW Storer N Berman, et al. 1996 The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men N Engl J Med 335 1 7 1:CAS:528:DyaK28Xkslamsr8%3D 10.1056/NEJM199607043350101 8637535 (Pubitemid 26230806)
18. CS Cooper PJ Perry AE Sparks, et al. 1998 Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men J Urol 159 441 443 1:CAS:528:DyaK1cXmsFOhs74%3D 10.1016/S0022-5347(01)63944-2 9649259 (Pubitemid 28049252)
19. MA Hoffman WC DeWolf A Morgentaler 2000 Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163 824 827 1:CAS:528: DC%2BD3cXhsVSjuro%3D 10.1016/S0022-5347(05)67812-3 10687985
20. ED Grober DJ Lamb M Khera, et al. 2008 Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy Int J Impot Res 20 561 565 1:CAS:528:DC%2BD1cXhtlCksrrJ 10.1038/ijir.2008.40 18843272
21. LS Marks NA Mazer E Mostaghel, et al. 2006 Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial JAMA 296 2351 2361 1:CAS:528:DC%2BD28Xht1ansb%2FM 10.1001/jama.296.19.2351 17105798 (Pubitemid 44749363)
22. M Khera M Miner R Bhattacharya, et al. 2010 PSA levels significantly rise after 3 months of testosterone replacement therapy in severely hypogonadal men in the Testim registry in the US (TRIUS) cohort [abstract 1379] J Urol 183 Suppl e533 10.1016/j.juro.2010.02.1008
23. HM Behre J Bohmeyer E Nieschlag 1994 Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls Clin Endocrinol (Oxf) 40 341 349 1:STN:280:DyaK2c3ksVSlsw%3D%3D 10.1111/j.1365-2265.1994.tb03929.x
24. SM Ho D Damassa PW Kwan, et al. 1985 Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats J Androl 6 279 290 1:CAS:528:DyaL28XhtVai 3877039
25. AM Traish DF Williams ND Hoffman HH Wotiz 1988 Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates Prog Clin Biol Res 262 145 160 1:CAS:528:DyaL1cXhs1CgsLs%3D 3375279
26. A Morgentaler AM Traish 2009 Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth Eur Urol 55 310 321 10.1016/j.eururo.2008.09.024 18838208 This manuscript describes the prostate saturation model and is the basis for our understanding of how testosterone may affect PSA and prostate cancer.
27. J Heracek R Hampl M Hill, et al. 2007 Tissue and serum levels of principal androgen in benign prostatic hyperplasia and prostate cancer Steroids 72 375 380 1:CAS:528:DC%2BD2sXjsVWitrs%3D 10.1016/j.steroids.2007.01.004 17368496 (Published erratum appears in Steroids 2008, 73:148.) (Pubitemid 46452717)
28. K Tomera D Gleason M Gittelman, et al. 2001 The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer J Urol 165 1585 1589 1:CAS:528:DC%2BD3MXjvVaitbs%3D 10.1016/S0022-5347(05)66353-7 11342922
29. PK Agarwal MG Oefelein 2005 Testosterone replacement therapy after primary treatment for prostate cancer J Urol 173 533 536 1:CAS:528: DC%2BD2MXitl2qtg%3D%3D 10.1097/01.ju.0000143942.55896.64 15643240
30. JM Kaufman RJ Graydon 2004 Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men J Urol 172 920 922 1:CAS:528:DC%2BD2cXms1Grsrg%3D 10.1097/01.ju.0000136269.10161.32 15310998 (Pubitemid 39096423)
31. M Khera ED Grober B Najari, et al. 2009 Testosterone replacement therapy following radical prostatectomy J Sex Med 6 1165 1170 1:CAS:528: DC%2BD1MXltFCgt7w%3D 10.1111/j.1743-6109.2009.01161.x 19207277
32. K Sathyamoorthy M Stein O Mohammed, et al. 2010 Testosterone replacement therapy in high risk patients following radical prostatectomy [abstract 1498] J Urol 183 Suppl e577 10.1016/j.juro.2010.02.1235
33. MF Sarosdy 2007 Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy Cancer 109 536 541 1:CAS:528:DC%2BD2sXitV2itrk%3D 10.1002/cncr.22438 17183557 (Pubitemid 46190961)
34. HH Davila CN Arison MK Hall, et al. 2008 Analysis of the PSA response after testosterone supplementation in patients who previously received management for their localized prostate cancer [abstract] J Urol 179 Suppl 428 10.1016/S0022-5347(08)61255-0
35. O Nabulsi R Tal G Gotto, et al. 2008 Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy J Urol 179 Suppl 426 427 10.1016/S0022-5347(08)61252-5
36. H Isbam M Fisch H Huland, et al. 2010 Testosterone treatment after radical prostatectomy for pathologically organ-confined prostate cancer: results from a multi-institutional study [abstract 1496] J Urol 183 Suppl e576 e577
37. MW Kattan JA Eastham AM Stapleton, et al. 1998 A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 766 771 1:STN:280:DyaK1c3ms1Krtg%3D%3D 10.1093/jnci/90.10. 766 9605647
38. JF Ward ML Blute J Slezak, et al. 2003 The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J Urol 170 1872 1876 10.1097/01.ju.0000091876.13656.2e 14532796 (Pubitemid 37254948)
39. IM van Oort DE Kok LA Kiemeney, et al. 2009 A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant." Urol Oncol 27 509 513 18625570
40. R Berger PG Febbo PK Majumder, et al. 2004 Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells Cancer Res 64 8867 8875 1:CAS:528:DC%2BD2cXhtVOmsL%2FK 10.1158/0008-5472.CAN-04-2938 15604246 (Pubitemid 39665491)
41. L Bonaccorsi M Muratori S Marchiani, et al. 2006 The androgen receptor and prostate cancer invasion Mol Cell Endocrinol 246 157 162 1:CAS:528:DC%2BD28XhsF2gtL4%3D 10.1016/j.mce.2005.11.006 16376012 (Pubitemid 43238410)
42. A Morgentaler EL Rhoden 2006 Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less Urology 68 1263 1267 10.1016/j.urology.2006.08.1058 17169647 (Pubitemid 44880344)
43. S Yamamoto J Yonese S Kawakami, et al. 2007 Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy Eur Urol 52 696 701 1:CAS:528:DC%2BD2sXhtVKgs7zN 10.1016/j.eururo.2007.03.052 17412490 (Pubitemid 47126163)
44. LR Miller AW Partin DW Chan, et al. 1998 Influence of radical prostatectomy on serum hormone levels J Urol 160 449 453 1:STN:280: DyaK1czktlCqsg%3D%3D 10.1016/S0022-5347(01)62922-7 9679896 (Pubitemid 29476696)
45. S Madersbacher G Schatzl C Bieglmayer, et al. 2002 Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis Urology 60 869 874 10.1016/S0090-4295(02)01893-9 12429318 (Pubitemid 35300357)
46. K Türkölmez M Bozlu K Sarica, et al. 1998 Effects of transurethral prostate resection and transurethral laser prostatectomy on plasma hormone levels Urol Int 61 162 167 10.1159/000030314 9933837 (Pubitemid 29074172)
47. IM Thompson DP Ankerst C Chi, et al. 2005 Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower JAMA 294 66 70 1:CAS:528:DC%2BD2MXlvVKmsrc%3D 10.1001/jama.294.1.66 15998892 (Pubitemid 41002840)
48. A Morgentaler M Sweeney R Bennett, et al. 2010 PSA and follow-up biopsy results in men who received testosterone therapy while on active surveillance for prostate cancer [abstract 1376] J Urol 183 Suppl e531 e532 10.1016/j.juro.2010.02.1005
49. M Khera 2009 Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men J Sex Med 6 Suppl 3 234 238 10.1111/j.1743-6109.2008.01159.x 19207279 This manuscript is the first to support the use of testosterone supplementation in penile rehabilitation following radical prostatectomy.
50. M Khera M Miner R Bhattacharya, et al. 2010 Testosterone supplementation significantly improves depression symptoms in hypogonadal men enrolled in the Testim registry in the US (TRIUS) [abstract 1479] J Urol 183 Suppl e578 10.1016/j.juro.2010.02.1236
51. AM Traish AT Guay 2006 Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence J Sex Med 3 382 404 1:CAS:528:DC%2BD28Xlt1arsb4%3D 10.1111/j.1743-6109.2006.00245.x 16681465
52. JP Mulhall A Morgentaler 2007 Penile rehabilitation should become the norm for radical prostatectomy patients J Sex Med 4 538 543 10.1111/j.1743-6109. 2007.00486.x 17498093 (Pubitemid 46779289)